# Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Clinical Trial

> **NCT00061451** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 48 (—)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Pemetrexed
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT00061451
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-12
- **Primary completion:** —
- **Final completion:** 2006-09
- **Target enrollment:** 48 (—)
- **Last updated:** 2010-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00061451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00061451, "Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Clinical Trial". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00061451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*